February 25, 2017 1:00 AM ET

Healthcare Providers and Services

Company Overview of Ranbaxy Pharmaceuticals, Inc.

Company Overview

Ranbaxy Pharmaceuticals, Inc. markets prescription and generic pharmaceutical products in the United States. Its product line includes anti-infective, cardiovascular, non-steroidal anti-inflammatory, anti-expectorant, analgesic, gastrointestinal, and central nervous system products, as well as controlled substances. The company was incorporated in 2004 and is based in Princeton, New Jersey. Ranbaxy Pharmaceuticals, Inc. is a subsidiary of Ranbaxy Inc.

600 College Road East

Suite 2100

Princeton, NJ 08540

United States

Founded in 2004





Key Executives for Ranbaxy Pharmaceuticals, Inc.

Head of Finance and Director
Chief Executive Officer of Ramnaxy and Managing Director of Ranbaxy
Age: 61
Vice President of Corporate Communications and Vice President of Government Affairs
Executive Director of Medical and Clinical Affairs
Senior Vice President, Regional Director of Americas and Director
Compensation as of Fiscal Year 2016.

Ranbaxy Pharmaceuticals, Inc. Key Developments

Cipher Pharmaceuticals Inc., Ranbaxy Pharmaceuticals, Inc. and Galephar Pharmaceutical Research, Inc. Enters into Settlement Agreement with Actavis Laboratories F1, Inc., Andrx Corp., Actavis, Inc. and Actavis Pharma, Inc

Cipher Pharmaceuticals Inc. along with its partners, Ranbaxy Pharmaceuticals, Inc. and Galephar Pharmaceutical Research, Inc. have entered into a settlement agreement with Actavis Laboratories F1, Inc., Andrx Corp., Actavis, Inc. and Actavis Pharma, Inc. that dismisses the patent litigation suit relating to Actavis' Abbreviated New Drug Application (ANDA) for a generic version of Absorica (isotretinoin capsules). As part of the settlement agreement, Cipher, Ranbaxy and Galephar have entered into a non-exclusive license agreement with Actavis under which Actavis may begin selling its generic version of Absorica in the U.S. on December 27, 2020 (approximately nine months prior to the expiration of the patents in September 2021) or earlier under certain circumstances. The settlement agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.

Similar Private Companies By Industry

Company Name Region
@ Home Medical, Inc. United States
@home approach, llc United States
@Home Care United States
1011 E. Pecan Grove Road, LLC United States
1104 Welsh Road Operations LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Ranbaxy Pharmaceuticals, Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.